BLS to Manufacture and Distribute Curaleaf International MID
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The device is the first EU Class IIa medical device designed for use with medical cannabis liquid inhalants, set to launch in November. This partnership is expected to create a new recurring revenue stream for Bioxyne, contributing significantly to their financial guidance for the upcoming fiscal year. The announcement highlights Bioxyne's commitment to expanding access to regulated inhalation technology in Australia.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Bioxyne
- Presentation on FY2025 Quarter 1 Results
- Initial German Purchase Orders and Import Permits
- BXN Full Year 2026 Guidance
- FY2025 Results Presentation
- Preliminary Final Report
Later from Bioxyne
- Funding from SOSE to Establish UK GMP Manufacturing Facility
- Supply Agreement Secured - Central American Cannabis Markets
- Quarterly Activities/Appendix 4C Cash Flow Report
- Appendix 4C Revised
- Presentation Results Q2 FY2026
Follow Bioxyne into a list and get an email when it puts out news.
Follow Bioxyne